Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

被引:28
|
作者
Goodin, Douglas S. [1 ]
Corwin, Michael [2 ,3 ]
Kaufman, David [2 ]
Golub, Howard [3 ]
Reshef, Shoshana [4 ]
Rametta, Mark J. [4 ]
Knappertz, Volker [5 ,6 ]
Cutter, Gary [7 ]
Pleimes, Dirk [8 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[3] Care Safe, Boston, MA USA
[4] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[5] Teva Pharmaceut, Frazer, PA USA
[6] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany
[7] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA
[8] Myelo Therapeut GmbH, Berlin, Germany
来源
PLOS ONE | 2014年 / 9卷 / 08期
关键词
SURVIVAL; MORTALITY;
D O I
10.1371/journal.pone.0105207
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Information on causes of death (CODs) for patients with multiple sclerosis (MS) in the United States is sparse and limited by standard categorizations of underlying and immediate CODs on death certificates. Prior research indicated that excess mortality among MS patients was largely due to greater mortality from infectious, cardiovascular, or pulmonary causes. Objective: To analyze disease categories in order to gain insight to pathways, which lead directly to death in MS patients. Methods: Commercially insured MS patients enrolled in the OptumInsight Research database between 1996 and 2009 were matched to non-MS comparators on age/residence at index year and sex. The cause most-directly leading to death from the death certificate, referred to as the "principal'' COD, was determined using an algorithm to minimize the selection of either MS or cardiac/pulmonary arrest as the COD. Principal CODs were categorized into MS, cancer, cardiovascular, infectious, suicide, accidental, pulmonary, other, or unknown. Infectious, cardiovascular, and pulmonary CODs were further subcategorized. Results: 30,402 MS patients were matched to 89,818 controls, with mortality rates of 899 and 446 deaths/100,000 person-years, respectively. Excluding MS, differences in mortality rate between MS patients and non-MS comparators were largely attributable to infections, cardiovascular causes, and pulmonary problems. Of the 95 excessive deaths (per 100,000 person-years) related to infectious causes, 41 (43.2%) were due to pulmonary infections and 45 (47.4%) were attributed to sepsis. Of the 46 excessive deaths (per 100,000 person-years) related to pulmonary causes, 27 (58.7%) were due to aspiration. No single diagnostic entity predominated for the 60 excessive deaths (per 100,000 person-years) attributable to cardiac CODs. Conclusions: The principal COD algorithm improved on other methods of determining COD in MS patients from death certificates. A greater awareness of the common CODs in MS patients will allow physicians to anticipate potential problems and, thereby, improve the care that they provide.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Multiple sclerosis prevalence in the United States commercially insured population
    Dilokthornsakul, Piyameth
    Valuck, Robert J.
    Nair, Kavita V.
    Corboy, John R.
    Allen, Richard R.
    Campbell, Jonathan D.
    [J]. NEUROLOGY, 2016, 86 (11) : 1014 - 1021
  • [2] Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States
    Zhou, Zhou
    Fan, Yanni
    Tang, Wenxi
    Liu, Xinyue
    Thomason, Darren
    Zhou, Zheng-Yi
    Macaulay, Dendy
    Fischer, Aryeh
    [J]. JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 920 - 927
  • [3] Causes of death among patients with multiple sclerosis
    Sumelahti, Marja-Liisa
    Hakama, Matti
    Elovaara, Irina
    Pukkala, Eero
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) : 1437 - 1442
  • [4] The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States
    Rice, J. Bradford
    White, Alan G.
    Galebach, Philip
    Korenblat, Kevin M.
    Wagh, Aneesha
    Lovelace, Belinda
    Wan, George J.
    Jamil, Khurram
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (08) : 1473 - 1480
  • [5] Naloxone dispensing among the commercially insured population in the United States
    Dunphy, Christopher
    Zhang, Kun
    Guy, Gery P., Jr.
    Jones, Christopher M.
    [J]. PREVENTIVE MEDICINE, 2021, 153
  • [6] The Burden of Hepatorenal Syndrome among Commercially-Insured and Medicare Patients in the United States
    Rice, J. B.
    White, Alan
    Galebach, Philip J.
    Korenblat, Kevin M.
    Wagh, Aneesha
    Lovelace, Belinda
    Wan, George J.
    Jamil, Khurram
    [J]. HEPATOLOGY, 2016, 64 : 1033A - 1034A
  • [7] Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States
    Woolley, J. Michael
    Bonafede, Machaon M.
    Maiese, Brett A.
    Lenz, Robert A.
    [J]. HEADACHE, 2017, 57 (09): : 1399 - 1408
  • [8] BURDEN OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS IN A COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES
    Rice, J. Bradford
    White, Alan
    Johnson, Michaels
    Simes, Mark
    Zuckerman, Peter
    Berman, Richard
    Hovland, Sara
    Huang, Xingyue
    [J]. HEPATOLOGY, 2020, 72 : 1059 - 1059
  • [9] Trends for Healthcare Cost among Commercially Insured Individuals with Multiple Sclerosis
    Kim, Youngran
    Krause, Trudy
    Blum, Philip
    Freeman, Leorah
    [J]. NEUROLOGY, 2019, 92 (15)
  • [10] Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets
    Kozma, Chris
    Evans, Emily
    Lebson, Lori
    Phillips, Amy
    Lobo, Carroline
    [J]. NEUROLOGY, 2023, 100 (17)